MAC and NMA HaploBMT with PT/Cy at Johns Hopkins
| Study . | Study period, N, age range (median, y) . | HSC source . | Cond. intensity . | Graft failure, % . | aGVHD grade II-IV, % . | aGVHD grade III-IV, % . | cGVHD, % . | NRM, % . | Relapse, % . | PFS/ EFS, % . | OS, % . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| McCurdy et al33 | 2002-2012, N = 372, 18-75 (55) | BM | NMA | 8 | 32 | 4 | 13 | 11 | 46 | 40 | 50 |
| Klein et al34 | 2003-2015, N = 40, 1-25 (20) | BM | NMA | 9 | 33 | 5 | 23 (7 moderate to severe) | 13 | 52 | 43 | 56 |
| Current study | 2008-2014, N = 96, 1-65 (42) | BM | MAC | 9 | 11 | 4 | 15 (6 moderate to severe) | 11 | 43 | 52 | 54 |
| Study . | Study period, N, age range (median, y) . | HSC source . | Cond. intensity . | Graft failure, % . | aGVHD grade II-IV, % . | aGVHD grade III-IV, % . | cGVHD, % . | NRM, % . | Relapse, % . | PFS/ EFS, % . | OS, % . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| McCurdy et al33 | 2002-2012, N = 372, 18-75 (55) | BM | NMA | 8 | 32 | 4 | 13 | 11 | 46 | 40 | 50 |
| Klein et al34 | 2003-2015, N = 40, 1-25 (20) | BM | NMA | 9 | 33 | 5 | 23 (7 moderate to severe) | 13 | 52 | 43 | 56 |
| Current study | 2008-2014, N = 96, 1-65 (42) | BM | MAC | 9 | 11 | 4 | 15 (6 moderate to severe) | 11 | 43 | 52 | 54 |
BM, bone marrow; Cond., conditioning; HSC, hematopoietic stem cell; PFS, progression-free survival.